N-Acetylaspartylglutamate in CNS Hypomyelination

M.M.C. Wamelink; E. Struys; U. Holwerda; E.A. Sistermans; R.M.L. van Spaendonk; D. Halley; M.A.A.P. Willemsen; C.A.J.M. Jakobs; M.S. van der Knaap; N.I. Wolf

doi:https://doi.org/10.1055/s-0031-1277176

N-Acetylaspartylglutamate in CNS Hypomyelination

M.M.C. Wamelink, E. Struys, U. Holwerda, E.A. Sistermans, R.M.L. van Spaendonk, D. Halley, M.A.A.P. Willemsen, C.A.J.M. Jakobs, M.S. van der Knaap, N.I. Wolf

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

CSF N-acetylaspartylglutamate (NAAG) has been found to be elevated in some hypomyelinating disorders. This study addressed the question whether it could be used as a marker for hypomyelination and as a means to distinguish between hypomyelinating disorders biochemically. We have measured CSF NAAG in a cohort of 28 patients with hypomyelination with known and unknown aetiology. NAAG was found to be elevated in 7 patients, but was normal in the majority, including patients with defined hypomyelinating disorders. CSF NAAG is not a universal marker of hypomyelination, and the mechanism of its elevation remains poorly understood

Original language	English
Pages (from-to)	74-77
Journal	Neuropediatrics
Volume	42
Issue number	2
DOIs	https://doi.org/10.1055/s-0031-1277176
Publication status	Published - 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://doi.org/10.1055/s-0031-1277176

Cite this

@article{2a294198fbb54415824b9ad04bc07ece,

title = "N-Acetylaspartylglutamate in CNS Hypomyelination",

abstract = "CSF N-acetylaspartylglutamate (NAAG) has been found to be elevated in some hypomyelinating disorders. This study addressed the question whether it could be used as a marker for hypomyelination and as a means to distinguish between hypomyelinating disorders biochemically. We have measured CSF NAAG in a cohort of 28 patients with hypomyelination with known and unknown aetiology. NAAG was found to be elevated in 7 patients, but was normal in the majority, including patients with defined hypomyelinating disorders. CSF NAAG is not a universal marker of hypomyelination, and the mechanism of its elevation remains poorly understood",

author = "M.M.C. Wamelink and E. Struys and U. Holwerda and E.A. Sistermans and {van Spaendonk}, R.M.L. and D. Halley and M.A.A.P. Willemsen and C.A.J.M. Jakobs and {van der Knaap}, M.S. and N.I. Wolf",

year = "2011",

doi = "https://doi.org/10.1055/s-0031-1277176",

language = "English",

volume = "42",

pages = "74--77",

journal = "Neuropediatrics",

issn = "0174-304X",

publisher = "Hippokrates Verlag GmbH",

number = "2",

}

TY - JOUR

T1 - N-Acetylaspartylglutamate in CNS Hypomyelination

AU - Wamelink, M.M.C.

AU - Struys, E.

AU - Holwerda, U.

AU - Sistermans, E.A.

AU - van Spaendonk, R.M.L.

AU - Halley, D.

AU - Willemsen, M.A.A.P.

AU - Jakobs, C.A.J.M.

AU - van der Knaap, M.S.

AU - Wolf, N.I.

PY - 2011

Y1 - 2011

N2 - CSF N-acetylaspartylglutamate (NAAG) has been found to be elevated in some hypomyelinating disorders. This study addressed the question whether it could be used as a marker for hypomyelination and as a means to distinguish between hypomyelinating disorders biochemically. We have measured CSF NAAG in a cohort of 28 patients with hypomyelination with known and unknown aetiology. NAAG was found to be elevated in 7 patients, but was normal in the majority, including patients with defined hypomyelinating disorders. CSF NAAG is not a universal marker of hypomyelination, and the mechanism of its elevation remains poorly understood

AB - CSF N-acetylaspartylglutamate (NAAG) has been found to be elevated in some hypomyelinating disorders. This study addressed the question whether it could be used as a marker for hypomyelination and as a means to distinguish between hypomyelinating disorders biochemically. We have measured CSF NAAG in a cohort of 28 patients with hypomyelination with known and unknown aetiology. NAAG was found to be elevated in 7 patients, but was normal in the majority, including patients with defined hypomyelinating disorders. CSF NAAG is not a universal marker of hypomyelination, and the mechanism of its elevation remains poorly understood

U2 - https://doi.org/10.1055/s-0031-1277176

DO - https://doi.org/10.1055/s-0031-1277176

M3 - Article

C2 - 21544765

SN - 0174-304X

VL - 42

SP - 74

EP - 77

JO - Neuropediatrics

JF - Neuropediatrics

IS - 2

ER -